Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab.

Autor: Greve AS; Department of Medicine, Viborg Regional Hospital, Viborg, Denmark. as.greve.munch@midt.rm.dk., Prakash S; Department of Neurology, Viborg Regional Hospital, Viborg, Denmark., Krag S; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark., Randers E; Department of Medicine, Viborg Regional Hospital, Viborg, Denmark.; Research Unit of Multimorbidity, Viborg Regional Hospital, Viborg, Denmark.
Jazyk: angličtina
Zdroj: Journal of nephrology [J Nephrol] 2023 Apr; Vol. 36 (3), pp. 659-661. Date of Electronic Publication: 2022 Nov 21.
DOI: 10.1007/s40620-022-01504-9
Abstrakt: We describe the case of a 24-year-old male patient with multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15 months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albuminuria. Kidney biopsy showed focal segmental glomerulosclerosis (FSGS) and Ocrelizumab treatment was stopped. Teriflunomide is less likely to have caused FSGS due to a three week wash-out period and a timespan of 15 months between the last Teriflunomide dose and development of albuminuria. Treatment with Ocrelizumab has been associated with organ-specific inflammation in MS-patients, thus an association between the development of FSGS and Ocrelizumab therapy is possible, and this case suggests considering this potential association.
(© 2022. The Author(s) under exclusive licence to Italian Society of Nephrology.)
Databáze: MEDLINE
Externí odkaz: